3
2
1

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

2026/07/22

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

2026/04/24

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

2026/03/04

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

2026/02/02

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

2026/01/19

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

2026/01/04

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.

2026-05-18

Breakthrough Organ Preservation Technology: Achieving Long-Term and Safe Preservation of Cells and Organs

Beyond organ transplantation, this non-toxic low-temperature preservation framework can be extended to long-term storage of stem cells, reproductive cells, and germplasm resources of endangered species, providing a universal technological foundation for biobanks, regenerative medicine, and other fields.

2026-05-11

Biomimetic "Soft Electrode" Enables 6-Month Single-Neuron Tracking, Ushering in "Invisible Bridge" for Brain-Computer Interfaces

As this technology continues to mature, we are moving one step closer to an era of safe, long-term, high-fidelity human-computer interaction.

2026-05-11

Smart Hydrogel Ushers Bone Regeneration into the Era of "Living Materials"

In the future, implanted materials will no longer be "dead scaffolds" but living materials that can converse with cells and adapt along with them.

2026-04-29

Breaking the Cryopreservation Bottleneck: New Pretreatment Technique Boosts NK Cell Recovery Rate to 90%–100% After Thawing

The clinical value of this approach lies in its extremely simple operation. It requires no specialized cryopreservation solutions or complex equipment, using only GMP‑grade compliant cytokines that can be removed by routine washing after pretreatment, posing no additional safety risks to patients and enabling rapid integration into existing cell production and cryopreservation workflows. As the large‑scale manufacturing of NK cells derived from umbilical cord blood and iPSCs becomes increasingly mature, combining this cryopreservation technology holds the potential to significantly reduce cell therapy costs and improve accessibility, opening new avenues for immunotherapy in hematological malignancies and solid tumors.

2026-04-20

Breaking the Bottleneck: New Technology Enables Deep Cryopreservation of Large-Scale Organs

Previously, only limited breakthroughs had been achieved internationally on 1 mL rat kidney models. The 10 mL rabbit kidney allogeneic transplantation achieved by the Technical Institute of Physics and Chemistry marks a milestone step toward clinical application of deep cryopreservation technology. In the future, this technology is expected to be extended to long-term preservation of human-scale organs, bringing revolutionary changes to organ transplantation.

2026-04-20

Crossing the Chasm: Artificial Neurons Achieve "Two-Way Dialogue" with Living Brain Cells for the First Time

This breakthrough holds tremendous potential not only for brain-computer interfaces and neural prosthetics (such as auditory, visual, and motor implants) but also lays a solid hardware foundation for building the next generation of efficient, brain-like computing systems.

< 1...456...28 >